These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 11282430

  • 1. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
    Shibayama T, Ueoka H, Nishii K, Kiura K, Tabata M, Miyatake K, Kitajima T, Harada M.
    Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N.
    Anticancer Res; 2003 Apr; 23(2A):885-93. PubMed ID: 12820318
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The diagnostic and prognostic value of ProGRP in lung cancer.
    Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T.
    Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
    [Abstract] [Full Text] [Related]

  • 7. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
    Peng Y, Wang Y, Li J, Hao X, Hu X.
    Zhongguo Fei Ai Za Zhi; 2016 Sep 20; 19(9):590-4. PubMed ID: 27666548
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
    Nisman B, Heching N, Biran H, Barak V, Peretz T.
    Tumour Biol; 2006 Sep 20; 27(1):8-16. PubMed ID: 16340245
    [Abstract] [Full Text] [Related]

  • 10. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.
    Niho S, Nishiwaki Y, Goto K, Ohmatsu H, Matsumoto T, Hojo F, Ohe Y, Kakinuma R, Kodama T.
    Lung Cancer; 2000 Mar 20; 27(3):159-67. PubMed ID: 10699689
    [Abstract] [Full Text] [Related]

  • 11. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
    Shen D, Han BB, Chen F, Wei BJ, Cui CJ, Wang GJ, Cui W.
    Zhonghua Yi Xue Za Zhi; 2017 Sep 12; 97(34):2657-2662. PubMed ID: 28910952
    [Abstract] [Full Text] [Related]

  • 12. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, Yamaguchi K.
    Anticancer Res; 1999 Sep 12; 19(4A):2673-8. PubMed ID: 10470218
    [Abstract] [Full Text] [Related]

  • 13. ProGRP: a new biomarker for small cell lung cancer.
    Molina R, Filella X, Augé JM.
    Clin Biochem; 2004 Jul 12; 37(7):505-11. PubMed ID: 15234231
    [Abstract] [Full Text] [Related]

  • 14. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
    Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ.
    Lung Cancer; 2003 Feb 12; 39(2):131-8. PubMed ID: 12581564
    [Abstract] [Full Text] [Related]

  • 15. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E, Kulpa JK, Sas-Korczyńska B, Korzeniowski S, Jakubowicz J.
    Anticancer Res; 2008 Feb 12; 28(5B):3027-33. PubMed ID: 19031951
    [Abstract] [Full Text] [Related]

  • 16. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM, Sauer-Eppel H, Bruzdziak TH.
    Anticancer Res; 2007 Feb 12; 27(4A):1911-5. PubMed ID: 17649794
    [Abstract] [Full Text] [Related]

  • 17. Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
    Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S, Iida K, Tamura K, Komiya T, Kawase I, Kikui N, Morino H, Fukuoka M.
    Br J Cancer; 1996 May 12; 73(10):1227-32. PubMed ID: 8630283
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
    Wu XY, Hu YB, Li HJ, Wan B, Zhang CX, Zhang B, Hu H, Zhang Q, Lv TF, Zhan P, Song Y.
    J Cell Mol Med; 2018 Sep 12; 22(9):4328-4334. PubMed ID: 29989303
    [Abstract] [Full Text] [Related]

  • 19. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
    Liu X, Zhang W, Yin W, Xiao Y, Zhou C, Hu Y, Geng S.
    Medicine (Baltimore); 2017 Nov 12; 96(46):e8258. PubMed ID: 29145241
    [Abstract] [Full Text] [Related]

  • 20. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
    Yang J, Li R, Li A.
    Zhonghua Zhong Liu Za Zhi; 2000 May 12; 22(3):216-8. PubMed ID: 11778234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.